ABSTRACT
This study aimed to determine discrepancies in the urinary glycosaminoglycan profiles of autism spectrum disorder (ASD) patients (n=9) when compared with those from healthy volunteers (HVs, n=3). The guardians and/or educators for each participant also returned a validated Autism Behavior Checklist (ABC). The urinary chondroitin sulfate (CS) concentration was 46.1% lower in the ASD group than in the HV group. The ABC score and the urinary CS concentration were negatively correlated (Spearman’s ρ=– 0.2635), indicating that as the severity of the clinical aspect of this disorder increased, the urinary CS concentration decreased. These results suggest that low CS concentrations in the urine may be associated with ASD, and could be measured using a fast and low-cost method for diagnostics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, grant number 2016/18066-6 to LT); and, in part, by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) - Finance Code 001, including fellowship to EL.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures performed in studies involving human participants were approved by Ethics Committee of Research of the Universidade Federal de Sao Paulo (no. 14667219.0.0000.5505) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent/assent was obtained from all participants or their guardians.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, grant number 2016/18066-6 to LT); and, in part, by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) – Finance Code 001, including fellowship to EL.
Conflict of interest: The authors declare that they have no conflict of interest.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.